Marinus Pharmaceuticals Stock Performance
| MRNS Stock | USD 1.44 0.04 2.70% |
The company secures a Beta (Market Risk) of 4.45, which conveys a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Marinus Pharmaceuticals will likely underperform. Marinus Pharmaceuticals has an expected return of -1.46%. Please make sure to verify Marinus Pharmaceuticals treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and period momentum indicator , to decide if Marinus Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Marinus Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in May 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Last Split Factor 1:4 | Dividend Date 2020-09-23 | Last Split Date 2020-09-23 |
1 | Sale by Christina Shafer of 2153 shares of Marinus Pharmaceuticals | 02/22/2024 |
2 | Disposition of 2153 shares by Christina Shafer of Marinus Pharmaceuticals at 9.56 subject to Rule 16b-3 | 03/25/2024 |
3 | Assenagon Asset Management S.A. Reduces Position in Marinus Pharmaceuticals, Inc. - MarketBeat | 04/03/2024 |
4 | Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635 | 04/05/2024 |
5 | Disposition of 2385 shares by Christina Shafer of Marinus Pharmaceuticals at 9.52 subject to Rule 16b-3 | 04/12/2024 |
6 | NXPL, MGRM and OCX among pre-market losers | 04/15/2024 |
7 | Marinus Pharmaceuticals, Inc. Might Not Be As Mispriced As It Looks After Plunging 86 | 04/16/2024 |
8 | Lost Money on Marinus Pharmaceuticals, Inc. Contact Levi Korsinsky Regarding an Ongoing Investigation | 04/17/2024 |
9 | INVESTIGATION ALERT The Schall Law Firm Announces it is Investigating Claims Against Marinus Pharmaceuticals, Inc. and Encourages Investors with Losses to Conta... | 04/19/2024 |
10 | Marinus Pharmaceuticals, Inc. Investigation Ongoing Contact Levi Korsinsky to Discuss Your Rights - MRNS | 04/22/2024 |
| Begin Period Cash Flow | 240.6 M |
Marinus |
Marinus Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 986.00 in Marinus Pharmaceuticals on January 24, 2024 and sell it today you would lose (838.00) from holding Marinus Pharmaceuticals or give up 84.99% of portfolio value over 90 days. Marinus Pharmaceuticals is currently does not generate positive expected returns and assumes 11.1873% risk (volatility on return distribution) over the 90 days horizon. In different words, 98% of stocks are less volatile than Marinus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Marinus Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Marinus Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Marinus Pharmaceuticals, and traders can use it to determine the average amount a Marinus Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1302
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MRNS |
Estimated Market Risk
| 11.19 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.46 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.13 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Marinus Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Marinus Pharmaceuticals by adding Marinus Pharmaceuticals to a well-diversified portfolio.
Marinus Pharmaceuticals Fundamentals Growth
Marinus Stock prices reflect investors' perceptions of the future prospects and financial health of Marinus Pharmaceuticals, and Marinus Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Marinus Stock performance.
| Return On Equity | -2.13 | ||||
| Return On Asset | -0.38 | ||||
| Operating Margin | (4.93) % | ||||
| Current Valuation | 40.67 M | ||||
| Shares Outstanding | 54.93 M | ||||
| Price To Earning | (4.80) X | ||||
| Price To Book | 24.57 X | ||||
| Price To Sales | 13.33 X | ||||
| Revenue | 30.99 M | ||||
| Gross Profit | (55.94 M) | ||||
| EBITDA | (130.93 M) | ||||
| Net Income | (141.41 M) | ||||
| Cash And Equivalents | 168.25 M | ||||
| Cash Per Share | 4.52 X | ||||
| Total Debt | 110.36 M | ||||
| Debt To Equity | 0.88 % | ||||
| Current Ratio | 8.41 X | ||||
| Book Value Per Share | 0.31 X | ||||
| Cash Flow From Operations | (118 M) | ||||
| Earnings Per Share | (2.63) X | ||||
| Market Capitalization | 81.02 M | ||||
| Total Asset | 170.91 M | ||||
| Retained Earnings | (571.93 M) | ||||
| Working Capital | 124.62 M | ||||
| Current Asset | 57.77 M | ||||
| Current Liabilities | 7.43 M | ||||
About Marinus Pharmaceuticals Performance
To evaluate Marinus Pharmaceuticals Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Marinus Pharmaceuticals generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Marinus Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Marinus Pharmaceuticals market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Marinus's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 354.42 | 372.15 | |
| Return On Tangible Assets | (0.83) | (0.87) | |
| Return On Capital Employed | (1.01) | (1.06) | |
| Return On Assets | (0.83) | (0.87) | |
| Return On Equity | (8.43) | (8.01) |
Things to note about Marinus Pharmaceuticals performance evaluation
Checking the ongoing alerts about Marinus Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Marinus Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Marinus Pharmaceuticals generated a negative expected return over the last 90 days | |
| Marinus Pharmaceuticals has high historical volatility and very poor performance | |
| Marinus Pharmaceuticals may become a speculative penny stock | |
| Marinus Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 30.99 M. Net Loss for the year was (141.41 M) with loss before overhead, payroll, taxes, and interest of (55.94 M). | |
| Marinus Pharmaceuticals currently holds about 168.25 M in cash with (118 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.52, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Marinus Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from accesswire.com: Marinus Pharmaceuticals, Inc. Investigation Ongoing Contact Levi Korsinsky to Discuss Your Rights - MRNS |
- Analyzing Marinus Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Marinus Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Marinus Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Marinus Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Marinus Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Marinus Pharmaceuticals' stock. These opinions can provide insight into Marinus Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Marinus Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more information on how to buy Marinus Stock please use our How to Invest in Marinus Pharmaceuticals guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Complementary Tools for Marinus Stock analysis
When running Marinus Pharmaceuticals' price analysis, check to measure Marinus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Marinus Pharmaceuticals is operating at the current time. Most of Marinus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Marinus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Marinus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Marinus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Marinus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Marinus Pharmaceuticals. If investors know Marinus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Marinus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.63) | Revenue Per Share 0.577 | Quarterly Revenue Growth 0.004 | Return On Assets (0.38) | Return On Equity (2.13) |
The market value of Marinus Pharmaceuticals is measured differently than its book value, which is the value of Marinus that is recorded on the company's balance sheet. Investors also form their own opinion of Marinus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Marinus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Marinus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Marinus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Marinus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Marinus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Marinus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.